Nuformix plc: Unaudited Half Year Results – Significant progress in lead programmes

Significant Progress in Lead Programmes

Cambridge, UK, 20th December 2018: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces the Company’s unaudited results for the six months ended 30 September 2018.


  • Pipeline Update:
    • Key development milestone achieved for NXP001 in Oncology Supportive Care triggering payment of £500,000
    • Additional patent filing broadening NXP002 applications in fibrotic conditions
    • Continued growth of pre-clinical portfolio following the development of new drug cocrystals
  • Strengthening Board:
    • Dr Chris Blackwell appointed to the Nuformix Board as a Non-Executive Director
  • Financial Highlights:
    • Reported net loss for the period was £642,633 (2017: £127,546 loss)
    • Operating profit before exceptional items for the reported period was positive at £114,020 (2017: £170,725 loss)

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...